Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB
- 15 December 2020
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 40 (6) , 1077-1090
Abstract
The mutagenic APOBEC3B (A3B) cytosine deaminase is frequently over-expressed in cancer and promotes tumour heterogeneity and therapy resistance. Hence, understanding the mechanisms that underlie A3B over-expression is important, especially for developing therapeutic approaches to reducing A3B levels, and consequently limiting cancer mutagenesis. We previously demonstrated that A3B is repressed by p53 and p53 mutation increases A3B expression. Here, we investigate A3B expression upon treatment with chemotherapeutic drugs that activate p53, including 5-fluorouracil, etoposide and cisplatin. Contrary to expectation, these drugs induced A3B expression and concomitant cellular cytosine deaminase activity. A3B induction was p53-independent, as chemotherapy drugs stimulated A3B expression in p53 mutant cells. These drugs commonly activate ATM, ATR and DNA-PKcs. Using specific inhibitors and gene knockdowns, we show that activation of DNA-PKcs and ATM by chemotherapeutic drugs promotes NF-κB activity, with consequent recruitment of NF-κB to the A3B gene promoter to drive A3B expression. Further, we find that A3B knockdown re-sensitises resistant cells to cisplatin, and A3B knockout enhances sensitivity to chemotherapy drugs. Our data highlight a role for A3B in resistance to chemotherapy and indicate that stimulation of A3B expression by activation of DNA repair and NF-κB pathways could promote cancer mutations and expedite chemoresistance.Keywords
Funding Information
- Cancer Research UK (C37/A18784, C37/A18784, C37/A18784, C37/A18784)
This publication has 58 references indexed in Scilit:
- An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancersNature Genetics, 2013
- DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegiseLife, 2013
- The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin systemBiochemical Journal, 2013
- APOBEC3B is an enzymatic source of mutation in breast cancerNature, 2013
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- A novel link to base excision repair?Trends in Biochemical Sciences, 2010
- APOBEC3 proteins mediate the clearance of foreign DNA from human cellsNature Structural & Molecular Biology, 2010
- A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53Proceedings of the National Academy of Sciences, 2009
- Participation of DNA repair in the response to 5-fluorouracilCellular and Molecular Life Sciences, 2008
- Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1Proceedings of the National Academy of Sciences of the United States of America, 2006